Skip to content

Released May 7, 2026, after the close

10-Q filed May 7, 2026, 37 days after period end · 0001628280-26-032293

Q1 2026 · 10-Q
Revenue$44.14M+6.5% vs Q1 2025−29.0% vs Q4 2025
Net Income-$18.87MN/M vs Q1 2025N/M vs Q4 2025
EPS Diluted-$0.15N/M vs Q1 2025no prior Q4 2025 on file
Gross Profit$21,254,000+5.4%
Operating Income-$18,463,000N/M
Operating Cash Flow-$2,736,000N/M
Free Cash Flowderived-$4,904,000N/M
Margins · derived
Gross margin48.2%−0.5 pt vs Q1 2025
Operating margin-41.8%−5.7 pt vs Q1 2025
Net margin-42.7%−15.2 pt vs Q1 2025

What the release said

The release

Same quarter

MetricQ1 2026Q1 2025Q1 2024Q1 2023
Revenue$44.14M$41.46M$44.86M$37.09M
Net Income-$18.87M-$11.40M-$6.17M-$6.81M
EPS Diluted-$0.15-$0.09-$0.05-$0.05

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Cytek Biosciences, Inc. · CIK 1831915 · Engraved from SEC EDGAR